|
CN202139694U
(zh)
|
2011-06-17 |
2012-02-08 |
清华大学 |
一种复式钢管混凝土柱与钢梁连接节点
|
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
CN105073768A
(zh)
|
2013-03-13 |
2015-11-18 |
达纳-法伯癌症研究所股份有限公司 |
Ras抑制剂及其用途
|
|
JP6473133B2
(ja)
|
2013-03-15 |
2019-02-20 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓｇ１２ｃの共有結合性阻害剤
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
AU2014331794C1
(en)
|
2013-10-10 |
2019-09-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C
|
|
JP6523303B2
(ja)
|
2014-01-17 |
2019-05-29 |
ノバルティス アーゲー |
Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
CN105899493B
(zh)
|
2014-01-17 |
2019-03-29 |
诺华股份有限公司 |
用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
ES2826443T3
(es)
|
2014-09-25 |
2021-05-18 |
Araxes Pharma Llc |
Inhibidores de proteínas mutantes KRAS G12C
|
|
JP2018513853A
(ja)
|
2015-04-10 |
2018-05-31 |
アラクセス ファーマ エルエルシー |
置換キナゾリン化合物およびその使用方法
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
CN112625028B
(zh)
|
2015-06-19 |
2024-10-29 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
|
ES2741746T3
(es)
|
2015-06-19 |
2020-02-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
MX388781B
(es)
|
2015-07-22 |
2025-03-20 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c.
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
|
JP7039489B2
(ja)
|
2016-05-18 |
2022-03-22 |
ミラティ セラピューティクス， インコーポレイテッド |
Ｋｒａｓ ｇ１２ｃ阻害剤
|
|
EA202092441A1
(ru)
|
2016-06-07 |
2021-05-21 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
|
MX383856B
(es)
|
2016-06-14 |
2025-03-14 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de shp2.
|
|
KR102598895B1
(ko)
|
2016-07-12 |
2023-11-07 |
레볼루션 메디슨즈, 인크. |
다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
|
|
US11529347B2
(en)
|
2016-09-22 |
2022-12-20 |
Relay Therapeutics, Inc. |
SHP2 phosphatase inhibitors and methods of use thereof
|
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
TW202500565A
(zh)
|
2016-10-24 |
2025-01-01 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其使用方法
|
|
WO2018119183A2
(en)
|
2016-12-22 |
2018-06-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MX2019008695A
(es)
|
2017-01-23 |
2019-09-11 |
Revolution Medicines Inc |
Compuestos biciclicos como inhibidores alostericos de shp2.
|
|
MX2019008696A
(es)
|
2017-01-23 |
2019-09-13 |
Revolution Medicines Inc |
Compuestos de piridina como inhibidores de shp2 alostericos.
|
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
US20200385364A1
(en)
|
2017-01-26 |
2020-12-10 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
KR20240026521A
(ko)
|
2017-03-23 |
2024-02-28 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
|
WO2018206539A1
(en)
|
2017-05-11 |
2018-11-15 |
Astrazeneca Ab |
Heteroaryl compounds that inhibit g12c mutant ras proteins
|
|
EA201992781A1
(ru)
|
2017-05-22 |
2020-04-01 |
Эмджен Инк. |
Ингибиторы g12c kras и способы их применения
|
|
AU2018271990A1
(en)
|
2017-05-25 |
2019-12-12 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
WO2018218133A1
(en)
|
2017-05-26 |
2018-11-29 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
|
CA3074690A1
(en)
|
2017-09-07 |
2019-03-14 |
Revolution Medicines, Inc. |
Shp2 inhibitor compositions and methods for treating cancer
|
|
MA50077A
(fr)
|
2017-09-08 |
2020-07-15 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
WO2019051469A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
|
|
EP3687997A1
(en)
|
2017-09-29 |
2020-08-05 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
|
MX2020003579A
(es)
|
2017-10-12 |
2020-07-22 |
Revolution Medicines Inc |
Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
|
|
HRP20230377T1
(hr)
|
2017-11-15 |
2023-06-23 |
Mirati Therapeutics, Inc. |
Inhibitori mutacije kras g12c
|
|
WO2019110751A1
(en)
|
2017-12-08 |
2019-06-13 |
Astrazeneca Ab |
Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents
|
|
BR112020009757A2
(pt)
|
2017-12-15 |
2020-11-03 |
Revolution Medicines, Inc. |
compostos policíclicos como inibidores alostéricos de shp2
|
|
US11453667B2
(en)
|
2018-01-19 |
2022-09-27 |
Medshine Discovery Inc. |
Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor
|
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
|
KR102614939B1
(ko)
|
2018-02-13 |
2023-12-19 |
블루레이 테라퓨틱스 (상하이) 컴퍼니 리미티드 |
피리미딘-융합고리 화합물 및 그의 제조방법과 용도
|
|
WO2019165073A1
(en)
|
2018-02-21 |
2019-08-29 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
|
RU2020133727A
(ru)
|
2018-03-21 |
2022-04-21 |
Сучжоу Пухе Биофарма Ко., Лтд. |
Ингибиторы shp2 и их применение
|
|
WO2019183364A1
(en)
|
2018-03-21 |
2019-09-26 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
|
|
SG11202009245TA
(en)
|
2018-03-21 |
2020-10-29 |
Relay Therapeutics Inc |
Shp2 phosphatase inhibitors and methods of use thereof
|
|
SG11202009793TA
(en)
|
2018-04-10 |
2020-10-29 |
Revolution Medicines Inc |
Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
|
|
KR102611661B1
(ko)
|
2018-05-02 |
2023-12-08 |
나비레 파르마, 인코퍼레이티드 |
Ptpn11의 치환된 헤테로사이클릭 억제제
|
|
ES2995514T3
(en)
|
2018-05-04 |
2025-02-10 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
WO2019213516A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
US11932633B2
(en)
|
2018-05-07 |
2024-03-19 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
EP3790886B1
(en)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
JP7174143B2
(ja)
|
2018-07-24 |
2022-11-17 |
大鵬薬品工業株式会社 |
Ｓｈｐ２活性を阻害するヘテロ二環性化合物
|
|
US11518770B2
(en)
|
2018-08-06 |
2022-12-06 |
Purdue Research Foundation |
Sesquiterpenoid analogs
|
|
LT3833670T
(lt)
|
2018-08-10 |
2024-06-25 |
Navire Pharma, Inc. |
6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dichlorfenil)-2-metilpirimidin-4(3h)-ono dariniai ir susiję junginiai kaip ptpn11 (shp2) inhibitoriai, skirti vėžiui gydyti
|
|
CN112839935A
(zh)
|
2018-09-26 |
2021-05-25 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
|
CN113473990A
(zh)
|
2018-10-08 |
2021-10-01 |
锐新医药公司 |
用于治疗癌症的shp2抑制剂组合物
|
|
US12187721B2
(en)
|
2018-10-17 |
2025-01-07 |
Array Biopharma Inc. |
Protein tyrosine phosphatase inhibitors
|
|
CN111138412B
(zh)
|
2018-11-06 |
2023-09-15 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物及其应用
|
|
JP2022506887A
(ja)
|
2018-11-07 |
2022-01-17 |
シャンハイ リンジーン バイオファーマ カンパニー リミテッド |
窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用
|
|
JP7377679B2
(ja)
*
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
CN113272303B
(zh)
|
2018-11-30 |
2024-09-17 |
上海拓界生物医药科技有限公司 |
嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
|
|
CN113164418A
(zh)
*
|
2018-12-05 |
2021-07-23 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
CN113316574B
(zh)
|
2019-01-31 |
2024-01-30 |
贝达药业股份有限公司 |
Shp2抑制剂及其应用
|
|
CN113365988B
(zh)
|
2019-01-31 |
2023-10-03 |
贝达药业股份有限公司 |
Shp2抑制剂及其应用
|
|
CN111647000B
(zh)
|
2019-03-04 |
2021-10-12 |
勤浩医药（苏州）有限公司 |
吡嗪类衍生物及其在抑制shp2中的应用
|
|
CA3127361A1
(en)
|
2019-03-07 |
2020-09-10 |
Merck Patent Gmbh |
Carboxamide-pyrimidine derivatives as shp2 antagonists
|
|
CA3127475A1
(en)
|
2019-04-08 |
2020-10-15 |
Merck Patent Gmbh |
Pyrimidinone derivatives as shp2 antagonists
|
|
EP3980128A1
(en)
|
2019-06-07 |
2022-04-13 |
Revolution Medicines, Inc. |
Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
|
|
CN117209471A
(zh)
|
2019-06-14 |
2023-12-12 |
北京盛诺基医药科技股份有限公司 |
一种shp2磷酸酶变构抑制剂
|
|
AU2020306124A1
(en)
|
2019-06-28 |
2022-02-03 |
Tuojie Biotech (Shanghai) Co., Ltd. |
Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
|
|
CN112300160A
(zh)
|
2019-08-01 |
2021-02-02 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物、其制备及应用
|
|
EP3772513A1
(en)
|
2019-08-09 |
2021-02-10 |
C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening |
Shp2 inhibitors
|
|
GB201911928D0
(en)
|
2019-08-20 |
2019-10-02 |
Otsuka Pharma Co Ltd |
Pharmaceutical compounds
|
|
CN114127053B
(zh)
|
2019-09-06 |
2023-06-13 |
四川科伦博泰生物医药股份有限公司 |
一种取代吡嗪化合物、其制备方法和用途
|
|
US20230010886A1
(en)
|
2019-09-23 |
2023-01-12 |
Suzhou Puhe BioPharma Co., Ltd. |
Shp2 inhibitors and uses thereof
|
|
AU2020354475A1
(en)
|
2019-09-24 |
2022-05-05 |
Relay Therapeutics, Inc. |
SHP2 phosphatase inhibitors and methods of making and using the same
|
|
CN112724145A
(zh)
|
2019-10-14 |
2021-04-30 |
杭州雷索药业有限公司 |
用于抑制shp2活性的吡嗪衍生物
|
|
WO2021088945A1
(zh)
|
2019-11-08 |
2021-05-14 |
南京圣和药业股份有限公司 |
作为shp2抑制剂的化合物及其应用
|
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
|
WO2022133731A1
(en)
*
|
2020-12-22 |
2022-06-30 |
Novartis Ag |
Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
|
|
TW202241414A
(zh)
*
|
2020-12-22 |
2022-11-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合以及ｋｒａｓ ｇ１２ｃ抑制劑用於治療癌症之用途
|